Liquidmetal Technologies (LQMT) Q4 2024 earnings summary

Executive summary

• Achieved steady revenue growth in 2024, driven by new product launches and expanded customer orders.

• Secured additional orders for the Evie Health Rings following FDA 510(k) clearance, opening new market opportunities.

• Expanded presence in the medical tools industry with new products moving from prototype to production.

• Entered fintech sector with a premium credit card prototype for a major U.S. financial institution.

Financial highlights

• 2024 revenues reached approximately $900,000, reflecting a steady increase from prior years.

• Ended 2024 with $22.5 million in liquid cash and investments.

• Achieved negative $800,000 EBITDA for 2024, an improvement of 50% over 2023.

• No debt on the balance sheet; corporate facility is debt-free and available for sale if needed.

Outlook and guidance

• Anticipates significant order volume increases for health monitoring solutions following FDA clearance.

• Focused on revenue growth, positive cash flow, and profitability, with steady progress toward these goals.

• Well positioned to fund growth with no going-concern issues.